Filter Results
:
(508)
Show Results For
-
All HBS Web
(508)
- People (2)
- News (133)
- Research (127)
- Events (2)
- Multimedia (5)
- Faculty Publications (71)
Show Results For
-
All HBS Web
(508)
- People (2)
- News (133)
- Research (127)
- Events (2)
- Multimedia (5)
- Faculty Publications (71)
- 25 Jul 2019
- Video
A Window on the Future of Science of Business: Harvard FUSION Symposium
- 04 Jun 2012
- News
Why Not Venture-Capital Philanthropy?
- July 1993
- Case
Genzyme Corporation: A Financing History
By: Timothy A. Luehrman and Andrew D. Regan
Genzyme Corp.'s financing history is unusual compared to most biotech companies. This case presents the sequence of financings employed by Genzyme, along with the product--market and corporate-development strategies adopted by Henri Termeer, Genzyme's CEO. As such, the...
View Details
Keywords:
History;
Marketing Strategy;
Financing and Loans;
Business Strategy;
Growth and Development Strategy;
Biotechnology Industry
Luehrman, Timothy A., and Andrew D. Regan. "Genzyme Corporation: A Financing History." Harvard Business School Case 294-005, July 1993.
- March 2011 (Revised February 2012)
- Case
Innovation and Growth at Actelion Ltd.
By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven...
View Details
Keywords:
Business Model;
Talent and Talent Management;
Innovation and Management;
Leadership;
Growth and Development Strategy;
Product Development;
Organizational Culture;
Research and Development;
Biotechnology Industry;
Pharmaceutical Industry;
Switzerland
Pisano, Gary P., Daniela Beyersdorfer, and Ruth Dittrich. "Innovation and Growth at Actelion Ltd." Harvard Business School Case 611-065, March 2011. (Revised February 2012.)
- September 2020 (Revised July 2021)
- Case
Moderna (A)
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer and Kerry Herman
In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19. The case explores how a company builds a digital organization, and leverages artificial intelligence and other digital...
View Details
Keywords:
COVID-19;
Vaccine;
Digital Organizations;
Organizational Structure;
Operations;
Management;
Health Pandemics;
Research and Development;
Goals and Objectives
Iansiti, Marco, Karim R. Lakhani, Hannah Mayer, and Kerry Herman. "Moderna (A)." Harvard Business School Case 621-032, September 2020. (Revised July 2021.)
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic...
View Details
Keywords:
Mergers and Acquisitions;
Growth and Development Strategy;
Product Development;
Research and Development;
Corporate Strategy;
Pharmaceutical Industry;
United States
Collis, David J., and Troy Smith. "Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc." Harvard Business School Case 707-509, November 2006. (Revised November 2007.)
- 30 Nov 2013
- News
Schumpeter: Going off the rails
- March 2018
- Supplement
Sandra Brown Goes Digital (C): Raising Quality in a Healthcare Company
By: Rosabeth Moss Kanter and Jonathan Cohen
Using digital and social media tools and lessons learned from prior change campaigns as a middle manager in a large biotech company, Sandra Brown continued in a new role in the quality division, engaging staff in a quality movement at the company. She had found a new...
View Details
Keywords:
Digital;
Grassroots Movement;
Managing Change;
Career Path;
Stakeholder Engagement;
Engagement;
Health Care Industry;
Quality;
Leading Change;
Performance Improvement;
Personal Development and Career;
Social Media;
Health Industry
Kanter, Rosabeth Moss, and Jonathan Cohen. "Sandra Brown Goes Digital (C): Raising Quality in a Healthcare Company." Harvard Business School Supplement 318-084, March 2018.
- 30 Dec 2010
- News
Shrink It, Cure It
- June 2018
- Teaching Note
Sandra Brown Goes Digital
By: Rosabeth Moss Kanter and Jonathan Cohen
As a middle manager at a biotechnology company, Sandra Brown harnessed digital tools and social media to engage others and build campaigns for change in the company. This Teaching Note presents strategies for teaching the Sandra Brown case series, which follows Brown's...
View Details
- October 2001 (Revised March 2008)
- Case
Anagene, Inc.
By: Robert S. Kaplan and Christina L. Darwall
An entrepreneurial, publicly traded biotech company has begun production and sales of its core product--cartridges that permit DNA samples to be analyzed on a microchip. In the early quarters, sales are difficult to forecast and the company has experienced fluctuating...
View Details
Keywords:
Cost Accounting;
Financial Reporting;
Production;
Performance Capacity;
Risk and Uncertainty;
Genetics;
Governing and Advisory Boards;
Biotechnology Industry;
California
Kaplan, Robert S., and Christina L. Darwall. "Anagene, Inc." Harvard Business School Case 102-030, October 2001. (Revised March 2008.)
- March 2011
- Case
MorphoSys AG: The Evolution of a Biotechnology Business Model
By: Gary P. Pisano, Ryan Johnson and Carin-Isabel Knoop
In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this profitability not by developing and selling its own drugs, but by licensing access to its proprietary library of human antibodies. Recently,...
View Details
Keywords:
Business Model;
Profit;
Intellectual Property;
Rights;
Risk Management;
Digital Platforms;
Product Development;
Business and Shareholder Relations;
Vertical Integration;
Biotechnology Industry;
Munich
Pisano, Gary P., Ryan Johnson, and Carin-Isabel Knoop. "MorphoSys AG: The Evolution of a Biotechnology Business Model." Harvard Business School Case 611-046, March 2011.
- April 1996 (Revised June 2000)
- Case
Boston Beer Company, Inc., The
Capital markets may have overcapitalized the craft brewing industry during a flurry of new IPOs. In the context of this "hot" IPO market each individual company's valuation may seem reasonable. However, after careful analysis of each company's financial statement and...
View Details
Keywords:
Initial Public Offering;
Analysis;
Valuation;
Industry Growth;
Food and Beverage Industry;
Boston
Hutton, Amy P., and Christopher Charron. "Boston Beer Company, Inc., The." Harvard Business School Case 196-138, April 1996. (Revised June 2000.)
- December 2005 (Revised May 2007)
- Case
Cynthia Fisher and the Rearing of ViaCell
By: Robert F. Higgins, Richard G. Hamermesh and Ingrid Vargas
Describes the start up of Viacord, a Boston-based medical services firm founded by Cynthia Fisher (HBS MBA) in 1993. Told from Fisher's perspective, the entrepreneur details the conceptualization and launch of the business and the many obstacles and expenses faced in...
View Details
Keywords:
Managerial Roles;
Business Growth and Maturation;
Entrepreneurship;
Business Startups;
Service Industry;
Health Industry;
Boston
Higgins, Robert F., Richard G. Hamermesh, and Ingrid Vargas. "Cynthia Fisher and the Rearing of ViaCell." Harvard Business School Case 806-002, December 2005. (Revised May 2007.)
- Research Summary
Career Histories and the Biotechnology Industry
Professor Higgins' other major project focuses on the consequences of individuals' career experiences for firms and industries. This second research stream centers on the careers of executives in the biotechnology industry.
Professor Higgins has written... View Details
- 2023
- Other Unpublished Work
Visions of Vision Pro
Daily ups and downs of the market are often driven by changes in interest-rate expectations and investor risk aversion. But over the long run, it's often technological change that is the primary driver of value. A decade ago, Tyler Cowen argued in his book The Great...
View Details
Cohen, Randolph B. "Visions of Vision Pro." August 2023. (LinkedIn Articles.)
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing...
View Details
Keywords:
AI;
Genetic Engineering;
Medicine;
Health Care and Treatment;
Genetics;
Innovation Strategy;
Business and Stakeholder Relations;
Medical Specialties;
Innovation and Invention;
Entrepreneurship;
Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
- 11 Apr 2019
- News
The DNA of Sustained Innovation
- July 2023
- Case
Moderna: Everything, Everywhere, All at Once
By: Satish Tadikonda, Shikhar Ghosh and William Marks
Coming out of the COVID-19 pandemic, Moderna was riding the successes of developing a vaccine in record time and helping stem the tide of the crisis. However, the company had grown at an incredible rate, more than doubled its number of employees, and had to put on hold...
View Details
Keywords:
Health Pandemics;
Selection and Staffing;
Growth Management;
Management Succession;
Retirement;
Biotechnology Industry
Tadikonda, Satish, Shikhar Ghosh, and William Marks. "Moderna: Everything, Everywhere, All at Once." Harvard Business School Case 824-021, July 2023.
- January 2020
- Case
Celata Bioinnovations
By: John R. Wells and Benjamin Weinstock
In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process....
View Details
Keywords:
Drug Development;
Drug Discovery;
Drug Trials;
Pharmaceutical Companies;
Pharmaceutical Company;
Pharmaceuticals;
Therapeutics;
Biologics;
Biotech;
Biotechnology;
Biopharmacy Company;
Biochemistry;
Technology Commercialization;
Technology Companies;
Drug Testing;
Startup;
Start-up;
Startups;
Start-ups;
Startup Financing;
Strategic Decision Making;
Strategic Decisions;
Strategic Evolution;
FDA;
Food And Drug Administration;
Clinical Trials;
Disease Management;
Market Attractiveness;
Market Entry;
Market Opportunities;
Health Disorders;
Technological Innovation;
Information Technology;
Commercialization;
Business Startups;
Finance;
Decision Making;
Strategy;
Market Entry and Exit;
Opportunities;
Pharmaceutical Industry;
Biotechnology Industry
Wells, John R., and Benjamin Weinstock. "Celata Bioinnovations." Harvard Business School Case 720-427, January 2020.